Drug Modules

Precision is our standard.

InsightRX Advantage

To develop each drug module, we carefully curate the best clinically-validated PK/PD models. Our Continuous Learning approach ensures that every model stays up-to-date and relevant while improving its predictive power for an increasingly complex patient set.

Model selection

  • InsightRX models are specific to a drug, patient population, and disease indication to provide the best predictive ability.
  • Models are checked for quality, completeness, and numerical stability.
  • The InsightRX computational API undergoes rigorous testing for quality assurance.

Model predictive checks

  • Prior to deploying a drug module, all models are checked for predictive performance utilizing your institution's data to ensure precision.

Continuous learning

  • InsightRX modules are continually re-optimized with data collected at scale over time.
  • Re-optimized modules provide a more precise understanding of unique patient subgroups, predictive covariates, drug-drug interactions, and pharmacogenomic effects.

Available Modules

Infectious Disease

  • Amikacin (Neonate, Pediatric, Adult)
  • Ceftazidime (Adult)
  • Cefuroxime (Adult)
  • Ciprofloxacin (Adult)
  • Flucloxacillin (Neonate, Adult)
  • Gentamicin (Neonate, Pediatric, Adult)
  • Meropenem (Neonate, Pediatric, Adult)
  • Piperacillin (Neonate, Pediatric, Adult)
  • Rifampicin (Adult)
  • Teicoplanin (Adult)
  • Tobramycin (Neonate, Pediatric, Adult)
  • Vancomycin (Neonate, Pediatric, Adult)
  • Voriconazole (Pediatric, Adult)

Bone Marrow Transplant

  • Anti-Thymocyte Globulin (Pediatric)
  • Busulfan (Neonate, Pediatric, Adult)
  • Fludarabine (Neonate, Pediatric)
  • Methotrexate (Pediatric)
  • Tacrolimus (Pediatric)

Coagulation Management

  • Enoxaparin (Neonate, Pediatric)
  • Factor VIII (Pediatric, Adult)

Solid Organ Transplant

  • Everolimus (Adult)
  • Tacrolimus (Adult)


  • Fosphenytoin (Pediatric)
  • Infliximab (Adult)
  • Methotrexate (Neonate, Pediatric)

InsightRX Labs: the Future of Research

Interested in Co-Developing a Module? We are always open to partnering with researchers to develop new or enhanced modules for pharmaceuticals. Contact us to discuss custom drug module co-development. Only together can we take precision medicine to new frontiers.

Project Mars: Oncology

Our oncology platform continuously learns from a patient’s pharmacological characteristics by analyzing routinely collected biomarkers and tumor imaging data. The platform empowers Oncologists to identify an optimal cancer therapy at an individualized dosing regimen by predicting tumor progression and the likelihood of drug-related toxic events such as myelosuppression. At a population level, providers can use the InsightRX powered analytics engine to analyze prescribing patterns, investigate patient subgroups, and improve treatment guidelines.

Status: Recruiting clinicians to utilize new module.

Project Venus: Ophthalmology

Our Ophthalmology precision therapy platform allows opthalmogists to predict the likelihood of treatment success by forecasting visual acuity score and retinal thickness, enabling the right therapy to be administered at the right time for patients with macular degeneration.

Status: Recruiting clinicians to utilize new module.

Project Mercury: Diabetes Management

Our Diabetes precision therapy platform dynamically learns from a patient’s disease and drug response characteristics - insulin levels, fasting plasma glucose and HbA1c profiles - in order to help clinicians optimize and adjust treatment of various Type 2 Diabetes medications.

Status: Recruiting thought-leaders to assist in development on module.

Project Saturn: Pharmacogenomics

We combine the mechanistic framework of quantitative pharmacology with pharmacogenetics to allow clinicians to identify optimal treatment and dosing regimens for an individual patient. The Insight PGX platform utilizes genetic determinants of drug response in a contextual and quantitative manner through a pharmacometric-driven framework across several therapeutic areas.

Status: Recruiting genetic counselors to provide feedback and input.